Study of Frailty, Sarcopenia, and Cognitive Impairment in Adults Over 18 Using Multidimensional Health Evaluations and Biomarker Analysis

What this Trial Is About

Researchers are conducting an observational study to assess how frailty and sarcopenia develop over time and to identify related biomarkers. This study involves participants from the earlier FRASNET study as well as patients with mild cognitive impairment and dementia who are being followed at the Neurologic Unit of the San Raffaele Hospital. The aim is to better understand the role of frailty in the progression and outcomes of various chronic diseases. Participants include older volunteers who were previously classified as robust or frail, and patients with cognitive impairments. The study involves comprehensive evaluations including completing scales and questionnaires, venous blood sampling, muscle and cardiac ultrasounds, electrocardiograms, and bioelectrical impedance analysis. These assessments are performed during multidimensional visits to gather detailed clinical and diagnostic data. During the study, participants will undergo these evaluations to monitor frailty, sarcopenia, and cognitive impairment markers. Researchers aim to identify new molecular markers of frailty and sarcopenia by February 2026 and assess how these markers relate to cognitive decline by April 2026. The study is sponsored by IRCCS San Raffaele and will follow participants from March 2024 until April 2026.

Age-related Conditions in the Context of Multimorbidity and Frailty: Relative Weight of Frailty in Determining the Course and Outcomes of Different Chronic Diseases and Viceversa